|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...87888990919293949596979899» |
- | metformin / Generic mfg.
Trial completion: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) (clinicaltrials.gov) - Dec 20, 2011
P3, N=173, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed
- linsitinib (ASP7487) / Sling Therap
Trial termination, Metastases: A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC (clinicaltrials.gov) - Dec 20, 2011
P2, N=23, Terminated, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Suspended --> Terminated; Company decided not to pursue the development of this drug in this patient population at this time
- ||||| Daklinza (daclatasvir) / BMS
Enrollment change, Combination therapy: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C (clinicaltrials.gov) - Dec 20, 2011
P3, N=120, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Suspended --> Terminated; Company decided not to pursue the development of this drug in this patient population at this time N=446 --> 120
- linsitinib (ASP7487) / Sling Therap
Enrollment change, Metastases: A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC (clinicaltrials.gov) - Dec 20, 2011
P2, N=23, Terminated, Sponsor: Astellas Pharma Inc
N=446 --> 120 N=132 --> 23
- |||||||||| Pegasys (pegylated interferon ? -2a) / Roche
New P3 trial: Phase 3 Study of Sofosbuvir and Ribavirin (clinicaltrials.gov) - Dec 20, 2011
P3, N=527, Completed, Sponsor: Gilead Sciences
- | GS-0938 / Gilead, Sovaldi (sofosbuvir) / Gilead
New P1 trial: Open-Label Hepatic Impairment Study (clinicaltrials.gov) - Dec 20, 2011
P1, N=24, Completed, Sponsor: Gilead Sciences
- Zokinvy (lonafarnib) / Eiger
New P2 trial: Lonafarnib for Chronic Hepatitis D (clinicaltrials.gov) - Dec 18, 2011
P2, N=14, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Xalkori (crizotinib) / Pfizer
Trial withdrawal, IO biomarker, Metastases: A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. (clinicaltrials.gov) - Dec 18, 2011
P1b, N=0, Withdrawn, Sponsor: Pfizer
N=132 --> 23 Not yet recruiting --> Withdrawn
- Xalkori (crizotinib) / Pfizer
Enrollment change, IO biomarker, Metastases: A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. (clinicaltrials.gov) - Dec 18, 2011
P1b, N=0, Withdrawn, Sponsor: Pfizer
Not yet recruiting --> Withdrawn N=180 --> 0
- hydroxychloroquine / Generic mfg.
Clinical: Treatment of Muscle Cramps in Patients With Liver Cirrhosis (clinicaltrials.gov) - Dec 18, 2011
P0, N=10, Enrolling by invitation, Sponsor: Mayo Clinic
- Trial completion: VAC-ADN: Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis (clinicaltrials.gov) - Dec 15, 2011
P1/2, N=70, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=180 --> 0 Active, not recruiting --> Completed
- spironolactone / Generic mfg.
Trial completion, Biopsy: Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Dec 15, 2011
P2, N=30, Completed, Sponsor: Aristotle University Of Thessaloniki
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Clinical: STANDAREA: Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care (clinicaltrials.gov) - Dec 14, 2011
P=N/A, N=121, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- | Avastin (bevacizumab) / Roche
New P4 trial, Combination therapy: AVAMET: Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer (clinicaltrials.gov) - Dec 14, 2011
P4, N=83, Recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
- | Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Takeda, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
New P1 trial: Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects (clinicaltrials.gov) - Dec 14, 2011
P1, N=42, Active, not recruiting, Sponsor: Exelixis
- ||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients (clinicaltrials.gov) - Dec 14, 2011
P1, N=72, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Daklinza (daclatasvir) / BMS
New P3 trial, Combination therapy: COMMAND-3: Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 13, 2011
P3, N=600, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- | sorafenib / Generic mfg.
Enrollment open, Metastases: SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 13, 2011
P3, N=400, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| faldaprevir (BI201335) / Boehringer Ingelheim
Trial completion, Combination therapy: Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2) (clinicaltrials.gov) - Dec 13, 2011
P2, N=719, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion: Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=32, Completed, Sponsor: University Hospital Freiburg
Active, not recruiting --> Completed Recruiting --> Completed
- furosemide / Generic mfg.
Enrollment change: ANSWER: Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis (clinicaltrials.gov) - Dec 11, 2011
P4, N=440, Recruiting, Sponsor: University of Bologna
Recruiting --> Completed N=600 --> 440
- furosemide / Generic mfg.
Enrollment open: ANSWER: Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis (clinicaltrials.gov) - Dec 11, 2011
P4, N=440, Recruiting, Sponsor: University of Bologna
N=600 --> 440 Not yet recruiting --> Recruiting
- ||||||| Trial completion: Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine (clinicaltrials.gov) - Dec 11, 2011
P3, N=455, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Rotarix (rotavirus vaccine) / GSK
Trial completion: A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar (clinicaltrials.gov) - Dec 11, 2011
P3, N=1375, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | GSK 2336805 / J&J
Trial completion: Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults (clinicaltrials.gov) - Dec 8, 2011
P1, N=28, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Avastin (bevacizumab) / Roche
Trial completion, Surgery: Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery (clinicaltrials.gov) - Dec 8, 2011
P2, N=62, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- isoflurane / Generic mfg.
Trial termination: Isoflurane Preconditioning for Liver Resections (clinicaltrials.gov) - Dec 7, 2011
P=N/A, N=8, Terminated, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed Recruiting --> Terminated; We no longer had an appropriate patient population.Study closed
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., floxuridine / Generic mfg.
Enrollment change: Isolated Liver Perfusion With Oxaliplatin (clinicaltrials.gov) - Dec 7, 2011
P1, N=10, Completed, Sponsor: University of Pittsburgh
Recruiting --> Terminated; We no longer had an appropriate patient population.Study closed N=30 --> 10
- isoflurane / Generic mfg.
Enrollment change: Isoflurane Preconditioning for Liver Resections (clinicaltrials.gov) - Dec 7, 2011
P=N/A, N=8, Terminated, Sponsor: Rutgers, The State University of New Jersey
N=30 --> 10 N=64 --> 8
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., floxuridine / Generic mfg.
Trial completion: Isolated Liver Perfusion With Oxaliplatin (clinicaltrials.gov) - Dec 7, 2011
P1, N=10, Completed, Sponsor: University of Pittsburgh
N=64 --> 8 Active, not recruiting --> Completed
- everolimus / Generic mfg.
New P2 trial, Metastases: Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 6, 2011
P2, N=30, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- ||| Olysio (simeprevir) / J&J, Medivir
Trial completion: TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers (clinicaltrials.gov) - Dec 6, 2011
P1, N=60, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Trial of TG4023 Combined With Flucytosine in Liver Tumors (clinicaltrials.gov) - Dec 6, 2011
P1, N=20, Completed, Sponsor: Transgene
Active, not recruiting --> Completed Recruiting --> Completed
- sorafenib / Generic mfg.
Enrollment change, Metastases: Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis (clinicaltrials.gov) - Dec 5, 2011
P1, N=6, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Completed N=30 --> 6
- || Olysio (simeprevir) / J&J, Medivir, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P3 trial, Combination therapy: TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINF?-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINF?-2a and Ribavirin Therapy (clinicaltrials.gov) - Dec 4, 2011
P3, N=766, Active, not recruiting, Sponsor: Janssen R&D Ireland
- | Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen (clinicaltrials.gov) - Dec 4, 2011
P1, N=18, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
- ||| Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Enrollment change, Head-to-Head: Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults (clinicaltrials.gov) - Dec 1, 2011
P4, N=213, Completed, Sponsor: GlaxoSmithKline
N=30 --> 6 N=495 --> 213
- TMC649 / J&J, Medivir
Trial termination, Combination therapy, Monotherapy: TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin (clinicaltrials.gov) - Dec 1, 2011
P1, N=14, Terminated, Sponsor: Tibotec BVBA
N=495 --> 213 Recruiting --> Terminated; Antiviral activity was considered insufficient to warrant further clinical development of TMC649128.
- TMC649 / J&J, Medivir
Enrollment change, Combination therapy, Monotherapy: TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin (clinicaltrials.gov) - Dec 1, 2011
P1, N=14, Terminated, Sponsor: Tibotec BVBA
Recruiting --> Terminated; Antiviral activity was considered insufficient to warrant further clinical development of TMC649128. N=50 --> 14
- Sutent (sunitinib) / Pfizer
Biomarker, Trial termination, Metastases: Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma (clinicaltrials.gov) - Nov 29, 2011
P2, N=4, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
N=50 --> 14 Recruiting --> Terminated; lack of inclusion
- Sutent (sunitinib) / Pfizer
Biomarker, Enrollment change, Metastases: Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma (clinicaltrials.gov) - Nov 29, 2011
P2, N=4, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Terminated; lack of inclusion N=45 --> 4
- Enrollment open: The Sleep, Liver Evaluation and Effective Pressure Study (clinicaltrials.gov) - Nov 29, 2011
P=N/A, N=120, Recruiting, Sponsor: Johns Hopkins University
N=45 --> 4 Not yet recruiting --> Recruiting
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Enrollment open: MEGANORM: Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease (clinicaltrials.gov) - Nov 29, 2011
P=N/A, N=64, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ganovo (danoprevir) / Roche, Ascletis, Pfizer, mericitabine (RG7128) / Gilead, Roche
New P2 trial: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Na (clinicaltrials.gov) - Nov 29, 2011
P2, N=43, Active, not recruiting, Sponsor: Hoffmann-La Roche
- || sorafenib / Generic mfg.
New P3 trial, Metastases: SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 28, 2011
P3, N=400, Recruiting, Sponsor: Assistance Publique - H
- ||||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche, Victrelis (boceprevir) / Roche, Merck (MSD)
New P2 trial, Combination therapy: A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C (clinicaltrials.gov) - Nov 28, 2011
P2, N=58, Completed, Sponsor: Hoffmann-La Roche
- ||||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
New P2 trial, Combination therapy: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C (clinicaltrials.gov) - Nov 28, 2011
P2, N=80, Completed, Sponsor: Hoffmann-La Roche
- | JNJ-47910382 / J&J
New P1 trial: A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 (clinicaltrials.gov) - Nov 28, 2011
P1, N=35, Completed, Sponsor: Janssen R&D Ireland
- sorafenib / Generic mfg.
New P2 trial, Metastases: Sorafenib VS TACE in HCC Patients With Portal Vein Invasion (clinicaltrials.gov) - Nov 27, 2011
P2, N=40, Recruiting, Sponsor: Seoul National University Hospital
- |||||||||| tenofovir disoproxil fumarate / Generic mfg.
New P3 trial: Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue (clinicaltrials.gov) - Nov 24, 2011
P3, N=166, Active, not recruiting, Sponsor: GlaxoSmithKline